ALNYLAM PHARMACEUTICALS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits of $69.98 million as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits · last filed 2026-02-12
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $69.98M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $62.11M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $67.15M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $52.99M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits |
|---|---|
| 2025-12-31 | $69.98M 10-K · filed 2026-02-12 |
| 2024-12-31 | $62.11M 10-K · filed 2026-02-12 |
| 2023-12-31 | $67.15M 10-K · filed 2025-02-13 |
| 2022-12-31 | $52.99M 10-K · filed 2024-02-15 |
| 2021-12-31 | $59.35M 10-K · filed 2023-02-23 |
| 2020-12-31 | $67.53M 10-K · filed 2022-02-10 |
| 2019-12-31 | $75.06M 10-K · filed 2021-02-11 |
| 2018-12-31 | $57.27M 10-K · filed 2020-02-13 |
| 2017-12-31 | $42.99M 10-K · filed 2019-02-14 |
| 2016-12-31 | $51.35M 10-K · filed 2018-02-15 |
| 2015-12-31 | $33.40M 10-K · filed 2017-02-15 |
| 2014-12-31 | $24.52M 10-K · filed 2016-02-12 |
| 2013-12-31 | $21.71M 10-K · filed 2015-02-13 |
| 2012-12-31 | $24.80M 10-K · filed 2014-02-20 |
| 2011-12-31 | $21.86M 10-K · filed 2013-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |